Dermatology
Pityriasis Rubra Pilaris
6
Pipeline Programs↗
1
Active Trials↗
5
Companies Involved↗
Pityriasis Rubra Pilaris is an early-stage landscape with 6 programs across 5 companies. The most active players are Novartis, Eli Lilly, Karuna Therapeutics, Inc., a Bristol Myers Squibb company. 1 therapy is approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 23
Phase 3
No programs
Approved1
Analysis
Modality Breakdown
6programs
Monoclonal antibody350%
Small molecule233%
Protein / enzyme117%
Modality classified for 100% of 6 pipeline programs.
Analysis
Trial Status
5
clinical trials
Completed3 · 60%
Recruiting1 · 20%
Terminated1 · 20%
Clinical Trials
Trial Activity
A Pilot Study of Alefacept for the Treatment of Pityriasis Rubra Pilaris
Terminated·—·Phase 4·NCT00815633·1 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)